dr. mcdermott on the role of vegf targeted therapy in rcc
Published 7 years ago • 120 plays • Length 0:45Download video MP4
Download video MP3
Similar videos
-
1:27
dr. mcdermott on vegf/pd-1 inhibition in rcc
-
1:51
dr. mcdermott on vegf plus pd-1 in renal cell carcinoma
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
3:39
anti-vegf/immunotherapy combinations in kidney cancer
-
2:09
comparing afami-cel with existing treatments in synovial sarcoma
-
7:18
vegf tki therapy in the adjuvant setting of rcc
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
1:22
dr. mcdermott on major findings of efficacy and safety of nivolumab in rcc
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
4:27
vegf-tki therapy in first-line mrcc
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
1:15
dr. mcdermott on single-agent versus combination immunotherapy in rcc
-
7:43
mrcc: resistance to vegf and i/o